Q3-FY26 · Q1 FY26
Zanthin derivative capacity expansion to 9,000 MT by H2 FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
AARTIPHARM / Q1-FY26 / promises
Measure what management said.
Aarti Pharmalabs · A quarter-by-quarter view of forward statements and whether delivery is visible yet.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Management delivery ledger
Promises over time.
Q3-FY26 · Q1 FY26
Atali greenfield plant commercial production by end of Q2 FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY26 · Q3 FY26
FY26 EBITDA flat to marginal growth
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q4-FY26 · Q3 FY26
CDMO revenue guidance for FY26 maintained
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q4-FY26 · Q3 FY26
Zanthin expansion mechanical completion by March 2026
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q4-FY26 · Q3 FY26
Atali plant resolution by Q4 FY26
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1